Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main (gene editing) focus: Undisclosed
Company stage: Commercial
Genome editing tool: CRISPR-Cas9
Funding stage: Public (OTC:DNPUF)
Location: Osaka, Osaka, Japan
Partners: ERS Genomics
Sumitomo Pharma is a Japan-based company with global operations. The company is mainly involved in the gene-editing space through its license agreement with ERS Genomics, which it entered into in April 2022. The lead gene-editing programmes coming from the license agreement are yet to be disclosed.